Contineum director granted 19,000 stock options
Contineum Therapeutics director Diego Miralles received a new stock option grant as part of standard board compensation.
Rhea-AI Filing Summary
Contineum Therapeutics director Diego Miralles received a new stock option grant as part of standard board compensation. He was awarded options over 19,000 shares of Class A common stock at an exercise price of $14.19 per share under the company’s 2024 Equity Incentive Plan.
The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic option for 19,000 shares after each regular annual meeting for continuing non-employee directors. The options vest in full on the earlier of June 26, 2027, or the next regular annual stockholder meeting, subject to his continuous service, and expire on June 25, 2036. Following this grant, Miralles holds 19,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 19,000 shares
Grant/Award
1 txn
Insider
Miralles Gines Diego
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 19,000 contracts (Direct)
Footnotes (1)
- F1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Key Figures
Option grant size: 19,000 shares
Exercise price: $14.19 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Option grant size
19,000 shares
Stock option award to director Diego Miralles
Exercise price
$14.19 per share
Strike price for newly granted options
Expiration date
June 25, 2036
Option term end for this grant
Total options held after grant
19,000 options
Direct holdings following transaction
Vesting date trigger
Earlier of June 26, 2027 or next annual meeting
Full vesting condition for the option grant
Key Terms
2024 Equity Incentive Plan, Non-Employee Director Compensation Program, stock option, Class A Common Stock
4 terms
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting"
stock option financial
"will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Class A Common Stock financial
"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Contineum Therapeutics (CTNM) director Diego Miralles receive in this Form 4 filing?
Diego Miralles received a grant of stock options for 19,000 shares of Contineum Therapeutics Class A common stock. The award is part of the company’s standard non-employee director compensation program under its 2024 Equity Incentive Plan.
What is the exercise price and term of Diego Miralles’ new Contineum (CTNM) stock options?
The new stock options have an exercise price of $14.19 per share and expire on June 25, 2036. This gives Miralles the right to buy 19,000 shares at that price anytime before the expiration date, once the options are vested.
When do Diego Miralles’ Contineum Therapeutics (CTNM) stock options vest?
The options vest in full on the earlier of June 26, 2027, or the next regular annual meeting of stockholders. Vesting is conditioned on Miralles’ continuous service as a non-employee director on Contineum’s board through that vesting date.
Under which plan were the new Contineum (CTNM) stock options to Diego Miralles granted?
The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan. They were issued pursuant to the company’s Non-Employee Director Compensation Program, which provides automatic annual stock option grants to continuing non-employee board members.
How many Contineum Therapeutics (CTNM) stock options does Diego Miralles hold after this transaction?
After this transaction, Miralles holds 19,000 stock options directly. This amount matches the newly granted options, indicating this award represents his full reported option position in this specific Form 4 filing excerpt.
AI-generated analysis. How Rhea-AI works. Not financial advice.
